12月17日 - ** CytokineticsCYTK.O股价盘前上涨3.1%至63.95美元
** 制药商称， (link) Myqorzo是其治疗阻塞性肥厚型心肌病的药物，已获得中国国家医药产品监督管理局的批准(NMPA)
** 赛诺菲SASY.PA拥有在大中华区开发和商业化治疗阻塞性和非阻塞性肥厚型心肌病药物的独家权利。
** CYTK仍有资格从赛诺菲获得高达1.425亿美元的开发和商业里程碑付款，以及未来销售的特许权使用费
** 美国食品和药物管理局的目标行动日期是12月26日，而欧盟执委会预计在2026年第一季度做出决定
** 截至上一交易日收盘，股价已累计上涨 31.9
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.